Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Breast Neoplasms 3Prostatic Neoplasms 2Neuroblastoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia 2Endometrial Neoplasms 2Congenital Abnormalities 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Pleuropulmonary blastoma 1Papillomavirus Infections 1Pain 1Neurofibrosarcoma 1Neoplasms 1Myeloproliferative Syndrome, Transient 1Meningioma 1Melanoma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Liposarcoma 1Leukemia, Eosinophilic, Acute 1

Interventions

ruxolitinib 1Observation 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Myeloproliferative Syndrome, Transient × Observation × Clear all
NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Children's Oncology Group

Phase 3 Withdrawn
MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡